Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents (Q35040797)

6 August 2017

1 reference

title

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents (English)

1 reference

6 August 2017

A Douglas Laird

1

1 reference

PubMed ID

12517254

6 August 2017

Julie M Cherrington

series ordinal

2

1 reference

PubMed ID

12517254

6 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

1 reference

6 August 2017

12

1 reference

6 August 2017

1

1 reference

6 August 2017

51-64

1 reference

Oncogenic kinase signalling

6 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Receptor tyrosine kinases as targets for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Growth factor signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

The microenvironment of the tumour-host interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Malignant glioma: genetics and biology of a grave matter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

STI571: a paradigm of new agents for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Class III receptor tyrosine kinases: role in leukaemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Identification of four new translocations involving FGFR1 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Design of growth factor antagonists with antiangiogenic and antitumor properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

VEGF: an update on biological and therapeutic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Pericyte loss and microaneurysm formation in PDGF-B-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Dysregulation of Met receptor tyrosine kinase activity in invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Angiopoietin-1 protects the adult vasculature against plasma leakage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Role of Src expression and activation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Src family kinases and HER2 interactions in human breast cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Signal transduction by the TCR for antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Activating SRC mutation in a subset of advanced human colon cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

HER-2/neu as a predictive marker of response to breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Use of proteomic patterns in serum to identify ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Tyrosine kinase inhibitors-ZD1839 (Iressa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.1.51

21 January 2018

Identifiers

DOI

10.1517/13543784.12.1.51

1 reference

6 August 2017

1 reference

PubMed ID

12517254